A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

Completed · Phase 3

Conditions studied: Hemophilia

In brief

Primary Objective: To characterize the frequency of bleeding episodes (BE) while receiving fitusiran treatment, relative to the frequency of bleeding episodes while receiving factor concentrate or bypassing agent (BPA) prophylaxis. Secondary Objectives: * To characterize the following while receiving fitusiran treatment, relative to receiving factor or BPA prophylaxis: * the frequency of spontaneous bleeding episodes * the frequency of joint bleeding episodes * health related quality of life (HRQOL) in participants greater than or equal to (\>=) 17 years of age * To characterize the frequency of bleeding episodes during the onset and treatment periods in participants receiving fitusiran. * To characterize the safety and tolerability of fitusiran. * To characterize the annualized weight-adjusted consumption of factor/BPA while receiving fitusiran treatment, relative to receiving factor or BPA prophylaxis.

Key facts

Study ID: NCT03549871
Run by: Genzyme, a Sanofi Company
People needed: 80
Starts: 2018-07-25
Expected to finish: 2022-03-25
Last updated by the study team: 2023-02-06

Who can join

Age: 12 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

Males, >=12 years of age.
Severe hemophilia A or B (as evidenced by a central laboratory measurement at screening or documented medical record evidence of FVIII less than (<) 1 percent (%) or FIX level less than or equal to (<=) 2%).
A minimum of 2 bleeding episodes required BPA treatment within the last 6 months prior to screening for participants with inhibitory antibodies to factor VIII or factor IX (Cohort A). A minimum of 1 bleeding episode required factor treatment within the last 12 months prior to screening for participants without inhibitory antibodies to factor VIII or factor IX (Cohort B).
Met either the definition of inhibitor or non-inhibitor participant as below:
Inhibitor: Use of BPAs for prophylaxis and for any bleeding episodes for at least the last 6 months prior to screening, and met one of the following Nijmegen-modified Bethesda assay results criteria:
Inhibitor titer of >=0.6 Bethesda Unit per milliliter (BU/mL) at screening, or
Inhibitor titer of <0.6 BU/mL at screening with medical record evidence of 2 consecutive titers >=0.6 BU/mL, or
Inhibitor titer of <0.6 BU/mL at screening with medical record evidence of anamnestic response
The subgroup of participants in Cohort A participants might additionally meet the following criteria to be eligible to start treatment with fitusiran directly after the screening period:
Hemophilia B with inhibitory antibody to Factor IX as defined above
Not responding adequately to BPA treatment (historical ABR >=20) prior to enrollment
In the opinion of the Investigator, with approval of Sponsor Medical Monitor, 6-month BPA prophylaxis period should be omitted.
Non-inhibitor: Use of factor concentrates for prophylaxis and for any bleeding episodes for at least the last 6 months prior to screening, and met each of the following criterion:
Nijmegen-modified Bethesda assay inhibitor titer of <0.6 BU/mL at screening and
No use of BPAs to treat bleeding episodes for at least the last 6 months prior to screening and
No history of immune tolerance induction therapy within the past 3 years prior to screening.
Documented prophylactic treatment with factor concentrates or BPAs for the treatment of hemophilia A or B for at least 6 months prior to screening.
Adherent to the prescribed prophylactic therapy for at least 6 months prior to screening per Investigator assessment.
Willed and complied with the study requirements and to provide written informed consent and assent.

You may not qualify if…

Known co-existing bleeding disorders other than hemophilia A or B.
AT activity <60% at screening.
Co-existing thrombophilic disorder.
Clinically significant liver disease.
Active Hepatitis C virus infection.
Acute or chronic Hepatitis B virus infection.
HIV positive with a CD4 count of <200 cells per microliter.
History of arterial or venous thromboembolism.
Inadequate renal function.
History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-Acetylgalactosamine (GalNAc).
History of intolerance to subcutaneous injection(s).
Any other conditions or comorbidities that made the participant unsuitable for enrollment or could interfere with participation in or completion of the study, per Investigator judgment.

Where it is running

Investigational Site Number 0139 — Los Angeles, California, United States
Investigational Site Number 6104 — Prahran, Australia
Investigational Site Number 8604 — Beijing, China
Investigational Site Number 4501 — Copenhagen, Denmark
Investigational Site Number 3303 — Lyon, France
Investigational Site Number 5301 — Crumlin, Ireland
Investigational Site Number 9701 — Ramat Gan, Israel
Investigational Site Number 3902 — Milan, Italy
Investigational Site Number 8101 — Nagoya, Japan
Investigational Site Number 8102 — Nishinomiya, Japan
Investigational Site Number 8104 — Saitama, Japan
Investigational Site Number 8109 — Tokyo, Japan
Investigational Site Number 6004 — Ampang, Malaysia
Investigational Site Number 6002 — Johor Bahru, Malaysia
Investigational Site Number 6003 — Kota Kinabalu, Malaysia
Investigational Site Number 5201 — San Pablo, Mexico
Investigational Site Number 8201 — Busan, South Korea
Investigational Site Number 8202 — Daejeon, South Korea
Investigational Site Number 8204 — Seoul, South Korea
Investigational Site Number 9002 — Adana, Turkey (Türkiye)
Investigational Site Number 9001 — Ankara, Turkey (Türkiye)
Investigational Site Number 9004 — Antalya, Turkey (Türkiye)
Investigational Site Number 9008 — Gaziantep, Turkey (Türkiye)
Investigational Site Number 9005 — Istanbul, Turkey (Türkiye)
Investigational Site Number 9010 — Izmir, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.